BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/12/2023 10:39:02 AM | Browse: 175 | Download: 552
 |
Received |
|
2023-06-07 19:02 |
|
Peer-Review Started |
|
2023-06-07 19:03 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-07-07 09:04 |
|
Revised |
|
2023-07-21 19:57 |
|
Second Decision |
|
2023-07-26 02:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-07-27 00:39 |
|
Articles in Press |
|
2023-07-27 00:39 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-27 08:26 |
|
Publish the Manuscript Online |
|
2023-10-12 10:39 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Silvana Ancona, Sara Signa, Chiara Longo, Giuliana Cangemi, Roberta Carfora, Enrico Drago, Alessandro La Rosa, Marco Crocco, Andrea Chiaro, Paolo Gandullia and Serena Arrigo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Serena Arrigo, MD, Pediatric Gastroenterology and Endoscopy Unit, IRCCS Istituto Giannina Gaslini, 5 Via Gerolamo Gaslini, Genova 16147, Italy. serenaarrigo@gaslini.org |
| Key Words |
Infantile-onset inflammatory bowel disease; Adalimumab; Loss of response; Dose escalation; Anti-drug antibodies; Case report |
| Core Tip |
Infantile-onset inflammatory bowel disease (IBD) frequently has a more severe course and a greater resistance to standard therapy than IBD in older children. Anti-tumor necrosis factor agents often lead to the production of anti-drug antibodies, resulting in loss of clinical response and disease progression. For this reason, the early detection of anti-drug antibodies is important, which may be possible with therapeutic drug monitoring. To date, commonly used strategies to overcome anti-drug antibodies are switching drugs or adding an immunomodulator, but a better option may be dose escalation. |
| Publish Date |
2023-10-12 10:39 |
| Citation |
Ancona S, Signa S, Longo C, Cangemi G, Carfora R, Drago E, La Rosa A, Crocco M, Chiaro A, Gandullia P, Arrigo S. Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease. World J Gastroenterol 2023; 29(38): 5428-5434 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i38/5428.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i38.5428 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
